X.T.L. Biopharmaceuticals Ltd. - ADR
XTLB
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.04M
Close$
$-0.44
120.1% downside
Current Fair Value
120.1% downsideOvervalued by 120.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $2.04 Million |
|---|---|
| Enterprise Value | $2.24 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-17 |
| Beta | 0.45 |
| Outstanding Shares | 420,652 |
Return
| Return on Equity | 404.33% |
|---|---|
| Return on Assets | -618.67% |
| Return on Invested Capital | 792.91% |
Valuation & Multiples
| P/E Ratio | -1 |
|---|---|
| PEG | 9.82 |
| Price to Sales | 2.18 |
| Price to Book Ratio | -2.18 |
| Enterprise Value to Revenue | 4.96 |
| Enterprise Value to EBIT | -1.11 |
| Enterprise Value to Net Income | -3 |
| Total Debt to Enterprise | 0.12 |
| Debt to Equity | -1.06 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
April 29, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 1.80%▼ 15.48% |
|---|---|
| Total Invested | $20,652▼ 88.22% |
| Investors Holding | 3▼ 3.00% |
ESG Score
No data
About X.T.L. Biopharmaceuticals Ltd.
2,020 employees
CEO: Joshua Levine